Antibiotics, probiotics and prebiotics in IBD

Nestle Nutrition Institute Workshop Series

Volumn 79, Issue , 2014, Pages 83-100

  Bernstein, Charles N ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ESCHERICHIA COLI NISSLE 1917;

ANTIINFECTIVE AGENT; PREBIOTIC AGENT; PROBIOTIC AGENT;

DIET THERAPY; DRUG EFFECTS; GASTROINTESTINAL TRACT; HUMAN; INFLAMMATORY BOWEL DISEASES; MICROBIOLOGY; MICROFLORA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION;

ANTI-BACTERIAL AGENTS; GASTROINTESTINAL TRACT; HUMANS; INFLAMMATORY BOWEL DISEASES; MICROBIOTA; PREBIOTICS; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION;

EID: 84929515206     PISSN: 16642147     EISSN: 16642155     Source Type: Book Series    
DOI: 10.1159/000360713     Document Type: Conference Paper

References (67)

1. Bernstein CN, Shanahan F. Disorders of a modern lifestyle-reconciling the epidemiology of inflammatory bowel diseases. Gut 2008; 57: 1185-1191
2. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel disease with time, based on systematic review. Gastroenterology 2012; 142: 46-54
3. Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-Analysis. Am J Gastroenterol 2011; 106: 661-673
4. Selby W, Pavli P, Crotty B, et al. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology 2007; 132: 2313-2319
5. Sartor RB. Does Mycobacterium avium subspecies paratuberculosis cause Crohn's disease? Gut 2005; 54: 896-898
6. Steinhart AH, Feagan BG, Wong CJ, et al. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 2002; 123: 33-40
7. Sutherland L, Singleton J, Sessions J, et al. Double blind, placebo-controlled trial of metronidazole in Crohn's disease. Gut 1991; 32: 1071-1075
8. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995; 108: 1617-1621
9. Rutgeerts P, Van Assche G, Vermeire S, et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2005; 128: 856-861
10. Holubar SD, Cima RR, Sandborn WJ, Pardi DS. Treatment and prevention of pouchitis after ileal pouch-Anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev 2010; 6: CD001176
11. Shen B, Achkar JP, Lashner BA, et al. Ciprofloxacin is more effective in treating acute pouchitis than metronidazole: a randomized clinical trial. Gastroenterology 2001; 120(suppl 1): A453
12. Madden MV, McIntyre AS, Nicholls RJ. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci 1994; 39: 1193-1196
13. ftp://ftp.fao.org/docrep/fao/009/a0512e/a0512e00.pdf (accessed July 22, 2013
14. Degnan FH. The US Food and Drug Administration and probiotics: regulatory categorization. Clin Infect Dis 2008; 46(suppl 2): S133-S136
15. Kruis W, Schütz E, Fric P, et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997; 11: 853-858
16. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53: 1617-1623
17. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet 1999; 354: 635-639
18. Ford AC, Achkar JP, Khan KJ, et al. Efficacy of 5-Aminosalicylates in ulcerative colitis: systematic review and meta-Analysis. Am J Gastroenterol 2011; 106: 601-616
19. Sood A, Midha V, Makharia GK, et al. The probiotic preparation, VSL#3 induces remission in patients with mild-To-moderately active ulcerative colitis. Clin Gatroenterol Hepatol 2009; 7: 1202-1209
20. Tursi A, Brandimarte G, Papa A, et al. Treatment of relapsing mild-To-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2010; 105: 2218-2227
21. Miele E, Pascarella F, Giannetti E, et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009; 104: 437-443
22. Wildt S, Nordgaard I, Hansen U, et al. A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. J Crohns Colitis 2011; 5: 115-121
23. Shanahan F, Guarner F, Wright AV, et al. A one year, randomised double-blind, placebo controlled trial of a Lactobacillus or a Bifidobacteria probiotic for maintenance of steroid induced remission of ulcerative colitis (abstract). Gastroenterology 2006; 130: A44
24. Kato K, Mizuno S, Umesaki Y, et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther 2004; 20: 1133-1141
25. Gionchetti P, Rizello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a doubleblind, placebo-controlled trial. Gastroenterology 2000; 119: 305-309
26. Gionchetti P, Rizello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003; 124: 1202-1209
27. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004; 53: 108-114
28. Pronio A, Montesani C, Butteroni C, et al. Probiotic administration in patients with ileal pouch-Anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm Bowel Dis 2008; 14: 662-668
29. Kuisma J, Mentula S, Jarvinen H, et al. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther 2003; 17: 509-515
30. Butterworth AD, Thomas AG, Akobeng AK. Probiotics for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2008; 3 : CD006634.pub2
31. Prantera C, Scribano ML, Falasco G, et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomized controlled trial with Lactobacillus GG. Gut 2002; 51: 405-409
32. Marteau P, Lemann M, Seksik P, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomized, double blind, placebo controlled GETAID trial. Gut 2006; 55: 842-847
33. Van Gossum A, Dewit O, Louis E, et al. Multicenter randomized-controlled clinical trial of probiotics ( Lactobacillus johnsonii , LA1) on early endoscopic recurrence of Crohn's disease after ileo-caecal resection. Inflamm Bowel Dis 2007; 13: 135-142
34. Madsen K, Backer J, Leddin D, et al. A randomized controlled trial of VSL#3 for the prevention of endoscopic recurrence following surgery for Crohn's disease. Gastroenterology 2008; 134(supp 1): A361
35. Busvaros A, Gunadalini S, Baldassano RN, et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis 2005; 11: 833-839
36. Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall FJ. Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2006; 4: CD004826
37. Vanderpool C, Yan F, Polk DB. Mechanisms of probiotic action: implications for therapeutic applications in inflammatory bowel diseases. Inflamm Bowel Dis 2008; 14: 1585-1596
38. Boyle RJ, Robins-Browne RM, Tang MLK. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr 2006; 83: 1256-1264
39. Vahabnezhad E, Mochon AB, Wozniak LJ, Ziring DA. Lactobacillus bacteremia associated with probiotic use in a pediatric patient with ulcerative colitis. J Clin Gastroenterol 2013; 47: 437-439
40. Besselink MGH, van Santvoort HC, Buskens E, et al. Probiotic prophylaxis in predicted severe acute-pancreatitis: a randomized, double-blind, placebo controlled trial. Lancet 2008; 371: 651-659
41. Jonkers D, Penders J, Masclee A, Pierik M. Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. Drugs 2012; 72: 803-823
42. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn's disease patients. PNAS 2008; 105: 16731-16736
43. Gibson GR, Probert HM, Van Loo J, et al. Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. Nutr Res Rev 2004; 17: 259-275
44. Langlands SJ, Hopkins MJ, Coleman N, et al. Prebiotic carbohydrates modify the mucosa associated microflora of the human large bowel. Gut 2004; 53: 1610-1616
45. Lindsay JO, Whelan K, Stagg AJ, et al. Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's Disease. Gut 2006; 55: 348-355
46. Ramirez-Farias C, Slezak K, Fuller Z, et al. Effect of inulin on the human gut microbiota: stimulation of Bifidobacterium adolescentis and Faecalibacterium prausnitzii . Br J Nutr 2009; 101: 541-550
47. Benjamin JL, Hedin CRH, Koutsoumpas A, et al. Randomized, double-blind, placebocontrolled trial of fructo-oligosaccharides in active Crohn's disease. Gut 2011; 60: 923-929
48. De Preter V, Joossens M, Ballet V, et al. Metabolic profiling of the impact of oligofructose-enriched inulin in Crohn's disease patients: a double-blind randomized controlled trial. Clin Transl Gastroenterol DOI: 10.1038/ctg.2012
49. Joossens M, De Preter V, Ballet V, et al. Effect of oligofructose-enriched inulin (OF-IN) on bacterial composition and disease activity of patients with Crohn's disease: results from a double-blinded randomized controlled trial. Gut 2012; 61: 958
50. Zimmerman MA, Singh N, Martin PM, et al. Butyrate suppresses colonic inflammation through HDAC1-dependent Fas upregulation and Fas-mediated apoptosis of T cells. Am J Physiol Gastrointest Liver Physiol 2012; 302: G1405-G1415
51. Casellas F, Borruel N, Torrejón A, et al. Oral oligofructose-enriched inulin supplementation in acute ulcerative colitis is well tolerated and associated with lowered fecal calprotectin. Aliment Pharmacol Ther 2007; 25: 1061-1067
52. Welters CF, Heineman E, Thunnissen FB, et al. Effect of dietary inulin supplementation of inflammation of pouch mucosa in patients with an ileal pouch-Anal anastomosis. Dis Colon Rectum 2002; 45: 621-627
53. Norris JM, Barriga K, Hoffenberg EJ, et al. Risk of celiac disease autoimmunity and timing of gluten introduction in the diet of infants at increased risk of disease. JAMA 2005; 293: 2343-2351
54. Shaw S, Blanchard JF, Bernstein CN. Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Am J Gastroenterol 2010; 105: 2687-2692
55. Shaw S, Blanchard JF, Bernstein CN. Association between early childhood otitis media and pediatric inflammatory bowel disease: an exploratory population-based analysis. J Pediatr 2013; 162: 510-514
56. Shaw S, Blanchard JF, Bernstein CN. Association between the use of antibiotics and new diagnoses of Crohn's disease and ulcerative colitis. Am J Gastroenterol 2011; 106: 2133-2142
57. Virta L, Auvinen A, Helenius H, et al. Association of repeated exposure to antibiotics with the development of pediatric Crohn's disease-A nationwide, register-based Finnish case-control study. Am J Epidemiol 2012; 175: 775-784
58. Hviid A, Svanström H, Frisch M. Antibiotic use and inflammatory bowel diseases in childhood. Gut 2011; 60: 49-54
59. Kronman MP, Zaoutis TE, Haynes K, et al. Antibiotic exposure and IBD development among children: a population-based cohort study. Pediatrics 2012; 130: 794-803
60. Card T, Logan RFA, Rodrigues LC, et al. Antibiotic use and the development of Crohn's disease. Gut 2004; 53: 246-250
61. Hildebrand H, Malmborg P, Askling J, et al. Early-life exposures associated with antibiotic use and risk of subsequent Crohn's disease. Scand J Gastroenterol 2008; 43: 961-966
62. Agostoni C, Braegger C, Decsi T, et al. Breastfeeding: a commentary by the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol Nutr 2009; 49: 112-125
63. Oozeer R, van Limpt K, Ludwig T, et al. Intestinal microbiology in early life: specific prebiotics can have similar functionalities as human-milk oligosaccharides. Am J Clin Nutr DOI: 10.3945/ajcn.112.038893
64. Moro G, Minoli I, Mosca M, et al. Dosagerelated bifidogenic effects of galacto-And fructooligosaccharides in formula-fed term infants. J Pediatr Gastroenterol Nutr 2002; 34: 291-295
65. Salvini F, Riva E, Salvatici E, et al. A specific prebiotic mixture added to starting infant formula has long-lasting bifidogenic effects. J Nutr 2011; 141: 1335-1339
66. Knol J, Scholtens P, Kafka C, et al. Colon microflora in infants fed formula with galactoand fructo-oligosaccharides: more like breast-fed infants. J Pediatr Gastroenterol Nutr 2005; 40: 36-42
67. Claesson MJ, Jeffery IB, Conde S, et al. Gut microbiota composition correlates with diet and health in the elderly. Nature 2012; 488: 178-184